Moreover, EGR1 upregulation has been linked to enhanced p53 activity and increased intracellular levels of p66, which may accelerate the progression of NAFLD to liver fibrosis (4, 5, 23–26). Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.